Cystic fibrosis in the era of precision medicine

Research output: Contribution to journalArticle

Abstract

The treatment of people with cystic fibrosis (CF) has been transformed by the availability of drugs that target the basic chloride defect in the disease. The use of drugs that target specific molecular defects embodies the goals of precision medicine, which incorporate preventive and therapeutic strategies and takes into account differences among individuals. However, the entirety of CF care, from diagnosis to understanding the clinical phenotype and developing a therapeutic strategy, depends on taking into account individual characteristics to achieve optimal outcomes. Future therapies are likely to be even more individualized ushering in a new era of precision medicine.

Original languageEnglish (US)
JournalPaediatric Respiratory Reviews
DOIs
StateAccepted/In press - 2017

Fingerprint

Precision Medicine
Cystic Fibrosis
Therapeutics
Individuality
Pharmaceutical Preparations
Chlorides
Phenotype

Keywords

  • CFTR
  • Cystic Fibrosis
  • Genotype
  • Phenotype
  • Precision Medicine

ASJC Scopus subject areas

  • Pediatrics, Perinatology, and Child Health
  • Pulmonary and Respiratory Medicine

Cite this

@article{d117f94cbfc9444bb7eb668a86972e9b,
title = "Cystic fibrosis in the era of precision medicine",
abstract = "The treatment of people with cystic fibrosis (CF) has been transformed by the availability of drugs that target the basic chloride defect in the disease. The use of drugs that target specific molecular defects embodies the goals of precision medicine, which incorporate preventive and therapeutic strategies and takes into account differences among individuals. However, the entirety of CF care, from diagnosis to understanding the clinical phenotype and developing a therapeutic strategy, depends on taking into account individual characteristics to achieve optimal outcomes. Future therapies are likely to be even more individualized ushering in a new era of precision medicine.",
keywords = "CFTR, Cystic Fibrosis, Genotype, Phenotype, Precision Medicine",
author = "Paranjape, {Shruti M} and Peter Mogayzel",
year = "2017",
doi = "10.1016/j.prrv.2017.03.001",
language = "English (US)",
journal = "Paediatric Respiratory Reviews",
issn = "1526-0542",
publisher = "W.B. Saunders Ltd",

}

TY - JOUR

T1 - Cystic fibrosis in the era of precision medicine

AU - Paranjape, Shruti M

AU - Mogayzel, Peter

PY - 2017

Y1 - 2017

N2 - The treatment of people with cystic fibrosis (CF) has been transformed by the availability of drugs that target the basic chloride defect in the disease. The use of drugs that target specific molecular defects embodies the goals of precision medicine, which incorporate preventive and therapeutic strategies and takes into account differences among individuals. However, the entirety of CF care, from diagnosis to understanding the clinical phenotype and developing a therapeutic strategy, depends on taking into account individual characteristics to achieve optimal outcomes. Future therapies are likely to be even more individualized ushering in a new era of precision medicine.

AB - The treatment of people with cystic fibrosis (CF) has been transformed by the availability of drugs that target the basic chloride defect in the disease. The use of drugs that target specific molecular defects embodies the goals of precision medicine, which incorporate preventive and therapeutic strategies and takes into account differences among individuals. However, the entirety of CF care, from diagnosis to understanding the clinical phenotype and developing a therapeutic strategy, depends on taking into account individual characteristics to achieve optimal outcomes. Future therapies are likely to be even more individualized ushering in a new era of precision medicine.

KW - CFTR

KW - Cystic Fibrosis

KW - Genotype

KW - Phenotype

KW - Precision Medicine

UR - http://www.scopus.com/inward/record.url?scp=85016440858&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85016440858&partnerID=8YFLogxK

U2 - 10.1016/j.prrv.2017.03.001

DO - 10.1016/j.prrv.2017.03.001

M3 - Article

C2 - 28372929

AN - SCOPUS:85016440858

JO - Paediatric Respiratory Reviews

JF - Paediatric Respiratory Reviews

SN - 1526-0542

ER -